Pharmacokinetic variability of anthelmintics: Implications for the treatment of neurocysticercosis

Expert Review of Clinical Pharmacology

Volumn 5, Issue 1, 2012, Pages 21-30

  Jung Cook, Helgi ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Instituto Nacional de Neurologa y Neurociruga   (Mexico)

Author keywords

albendazole; bioavailability; drug interactions; neurocysticercosis; pharmacokinetics; praziquantel

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; AZITHROMYCIN; CARBAMAZEPINE; CIMETIDINE; DEXAMETHASONE; IVERMECTIN; PHENOBARBITAL; PHENYTOIN; PRAZIQUANTEL;

AFRICA; AREA UNDER THE CURVE; ASIA; CENTRAL AMERICA; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; EPILEPSY; HUMAN; IMMUNE RESPONSE; INTRACRANIAL PRESSURE; LARVA; NEUROCYSTICERCOSIS; NONHUMAN; REVIEW; SOUTH AMERICA; TAENIA SOLIUM;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; HUMANS; NEUROCYSTICERCOSIS; PRAZIQUANTEL; TREATMENT OUTCOME;

EID: 83055163334     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.72     Document Type: Review

References (49)

1. Fleury A, Moreno J, Valez P et al. Neurocysticerosis, a persisting health problem in Mexico. PLOS Negl. Trop. Dis. 4(8), 1-3 (2010).
2. Prasad KN, Prasad A, Verma A et al. Human cysticercosis and Indian scenario: A review. J. Biosci. 3, 571-582 (2008).
3. Esquivel A, Diaz-Otero F, Gimenez- Roldan S. Growing frequency of neurocysticercosis in Madrid (Spain). Neurologia 20, 116-120 (2005).
4. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: Review of an important emerging infection. Neurology 63, 1559-1564 (2004).
5. DeGiorgio C, Medina MT, Durón R et al. Neurocysticercosis. Epilepsy Curr. 4, 107-111 (2004).
6. Nash TE, Singh G, White AC et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 67(7), 1120-1127 (2006).
7. Jung H, Cárdenas G, Sciutto E, Fleury A. Medical treatment for neurocysticercosis: drugs, indications and perspectives. Curr. Top. Med. Chem. 8, 424-433 (2008).
8. Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: cysticidal drugs for neurocysticercosis: Albendazole and praziquantel. Ann. Intern. Med. 145, 43-51 (2006).
9. Carpio A, Kelvin EA, Bagiella E et al.; Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment on neurocysticercosis: A randomised controlled trial. J. Neurol. Neurosurg. Psychiatry 79, 1050-1055 (2008).
10. Góngora-Rivera F, Soto-Hernández JL, González Esquivel D et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cisticercosis. Neurology 66, 436-438 (2006).
11. Diazgranados-Sanchez JA, Barrios-Arrázola G, Costal JL, Burbano-Pabon J, Pinzón- Bedova J. Ivermectin as therapeutic alternative in neurocysticercosis that is resistant to conventional pharmacological effect treatment. Rev. Neurol. 46, 671-674 (2008).
12. Rocha MA Jr, Santos JM, Gomes EC et al. Treatment of cerebral cysticercosis with albendazole in elevated dosages. Arq. Neuropsiquiatr. 66, 114-116 (2008).
13. Cárdenas G, Carrillo-Meza R, Jung H, Sciutto E, Soto Hernandez JL, Fleury A. Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: A case series. BMC Neurol. 10, 162-165 (2010).
14. Reich MR, Govindaraj R. Dilemmas in drug development for tropical diseases: experiences with praziquantel. Health Policy 44, 1-18 (1998).
15. Robles V, Chavarria M. Report of a clinical case of cerebral cysticercosis treated medically with a new drug: praziquantel. Salud. PÚblica Mex. 21, 603-618 (1998).
16. Markoski M, Trindade E, Cabrera G et al. Praziquantel and albendazole damaging action on in vitro developing Mesocestoides corti. Parasitol. Int. 55, 51-61 (2006).
17. Li XQ, Björkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolize anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 59, 429-442 (2003).
18. Meier H, Blaschke G. Investigation of praziquantel metabolism in isolated rat hepatocytes. J. Pharm. Biomed. Anal. 26, 409-415 (2001).
19. Leopold G, Unguthern W, Groll E et al. Clinical pharmacology in normal volunteers of praziquantel. A new drug against schistosomes and cestodes. Eur. J. Clin. Pharmacol. 14, 281-291 (1978).
20. Watt G, White N, Padre L et al. Praziquantel pharmacokinetics and side effects in Schistosoma japonicum infected patients with liver disease. J. Infect. Dis. 157, 530-535 (1988).
21. Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J. Clin. Pharm. Ther. 32, 585-593 (2007).
22. Na-Bangchang K, Kietinun S, Pawa K, Hanpitakpong W, Lazdins J. Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans. R. Soc. Trop. Med. Hyg. 100, 325-345 (2006).
23. Jung H, Medina R, Castro N, Corona T, Sotelo J. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single day therapeutic regimen. Antimicrob. Agents Chemother. 41, 1256-1259 (1997).
24. Castro N, Jung H, Medina R, Gonzalez-Esquivel D, Lopez M, Sotelo J. Interaction between grapefruit juice and praziquantel in humans. Antimicrob. Agents Chemother. 46, 1614-1616 (2002).
25. Desai J. Perspectives on interactions between antiepileptic drugs and antimicrobial agents. Epilepsia 49(Suppl. 6), 47-49 (2008).
26. Ridtitid W, Wongnawa M, Mahatthanatrakul W, Punyo J, Sunbhanich M. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin. Pharmacol. Ther. 72, 505-513 (2002).
27. Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob. Agents Chemother. 44, 2903-2904 (2000).
28. Escobedo F, Penagos P, Rodriguez J et al. Albendazole therapy for neurocysticercosis. Arch. Int. Med. 147, 738-741 (1987).
29. Lacey E, Prichard RK. Interactions of benzimidazoles (BZ) with tubulin from BZ-sensitive and BZ-resistant isolates of Haemonchus contortus. Mol. Biochem. Parasitol. 19, 171-181 (1986).
30. Rawden HC, Kokwaro GO, Ward S, Edwards G. Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br. J. Clin. Pharmacol. 49, 313-322 (2000).
31. Marques MP, Takayanagui OM, Bonato PS et al. Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis. Chirality 11, 218-223 (1999).
32. Abdel-Tawab A, Bradley M, Ghazaly E, Horton H, El-Setouhy M. Albendazole and its metabolites in the breast milk of lactantig women following a single oral dose of albendazole. Br. J. Clin. Pharmacol. 68, 737-742 (2009).
33. Merino G, Jonker JW, Wagenaar E et al. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab. Dispos. 33, 614-618 (2005).
34. Marriner E, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur. J. Clin. Pharmacol. 30, 705-708 (1986).
35. Takayanagui O, Bonato P, Dreossi S, Lanchote VL. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. Br. J. Clin. Pharmacol. 54, 125-130 (2002).
36. Castro N, Márquez-Caraveo C, Brundage RC et al. Population pharmacokinetics of albendazole in patients with neurocysticercosis. Int. J. Clin. Pharmacol. Ther. 47, 679-685 (2009).
37. Mares S, Jung H, Temuchino A, González D. Influence of Mexican diet on the bioavailability of albendazole. Basic Clin. Pharmacol. Toxicol. 7, 1742-1743 (2005).
38. Lanchote VL, Garcia FS, Dreossi SA, Takayanagui OM. Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther. Drug Monit. 24, 338-345 (2002).
39. Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am. J. Trop. Med. Hyg. 66, 260-263 (2002).
40. Takayanagui OM, Lanchote VL, Marques MPC, Bonato PS. Therapy for neurocysticercosis. pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther. Drug Monit. 19, 51-55 (1997).
41. Lima RM, Ferreira MAD, Ponte TMJ et al. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity. Br. J. Clin. Pharmacol. 71, 528-535 (2010).
42. Garcia H, Lescano A, Lanchote V et al. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. Br. J. Clin. Pharmacol. 72, 77-84 (2011).
43. Amsden G, Gregory T, Michalak CH, Glue P, Knirsch CH. Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. Am. J. Trop. Med. Hyg. 76(6), 1153-1157 (2007).
44. Casulli A, Gomez MA, Gallinella B, Turchetto L, Poizo E. Hydroxypropyl-beta-cyclodextrin improves the effectiveness of albendazole against encapsulated larvae of Trichinella spiralis in a murine model. J. Antimicrob. Chemother. 58, 886-890 (2006).
45. Kalaiselvan R, Mohanta G, Madhusudan S, Manna P, Manavalan R. Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Pharmazie 62, 604-607 (2007).
46. Ravichandran R. In vivo pharmacokinetic studies of albendazole nanoparticulate oral formulations for improved bioavailability. Int. J. Green Nanotechnol. Biomed. 2, 46-53 (2010).
47. Yang Li, Geng Y, Li H, Yu J, Chang Y. Enhancement of the oral bioavailability of praziquantel by incorporation into solid nanoparticles. Pharmazie 64, 86-89 (2009).
48. Metwally A, Bennett JL, Botros S, Ebeid F, El Attar Gel D. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacol. Res. 31, 53-59 (1995).
49. Rigter IM, Schipper HG, Koopmans RP et al. Relative bioavailability of three newly developed albendazole formulations: A randomized crossover study with healthy volunteers. Antimicrob. Agents Chemother. 48, 1051-1054 (2004).